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Purpose: Therapeutic efficacy is routinely assessed by measurement of lesion size 
using flatmount retinas and confocal microscopy in the laser-induced choroidal 
neovascularization (L-CNV) rodent model. We investigated whether optical coherence 
tomography (OCT) quantification, using an ellipsoid volume measurement, was 
comparable to standard ex vivo evaluation methods for this model and whether this 
approach could be used to monitor treatment-related lesion changes. 
Methods: Bruch’s membrane was ruptured by argon laser in the dilated eyes of 
C57BL/6J mice, followed by intravitreal injections of anti-VEGF164 or vehicle, or no 
injection. In vivo OCT images were acquired using Micron III or InVivoVue systems at 7, 
10, and/or 14 days post-laser and neovascular lesion volume was calculated as an 
ellipsoid. Subsequently, lesion volume was compared to that calculated from confocal 
Z-stack images of agglutinin stained choroidal flatmounts. 
Results: Ellipsoid volume measurement of orthogonal 2D OCT images obtained from 
different imaging systems correlated with ex vivo lesion volumes for L-CNV 
(Spearman’s ρ = 0.82, 0.75, and 0.82 at days 7, 10, and 14, respectively). Ellipsoid 
volume calculation allowed temporal monitoring and evaluation of CNV lesions in 
response to anti-VEGF treatment. 
Conclusions: Ellipsoid volume measurements allow rapid, quantitative use of OCT for 
assessment of CNV lesions in vivo. This novel method can be used with different OCT 
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imaging systems with sensitivity to distinguish between treatment conditions. It may 
serve as a useful adjunct to the standard ex vivo confocal quantification, to assess 
therapeutic efficacy in preclinical models of CNV, and in models of other ocular 
diseases. 
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Choroidal neovascularization (CNV) is the aberrant growth of new blood vessels 
originating from the choroid into the subretinal space through a break in Bruch’s 
membrane.1 These new vessels can lead to vascular leakage, hemorrhage, formation of 
fibrovascular membranes, retinal detachment and eventually, if not treated, to a fibrous 
scar. 
CNV is a major cause of visual loss and is implicated in several neovascular eye 
diseases such as the wet (or exudative) form of age-related macular degeneration 
(AMD).2 Wet AMD is responsible for about 90% of AMD-related blindness in individuals 
over the age of 55, with about 200,000 new cases diagnosed every year in the United 
States alone.3, 4 Laser-induced CNV (L-CNV) is a frequently used experimental 
technique in mice and rats that induces breaks in Bruch’s membrane and stimulates 
blood vessel growth from the choriocapillaris.5 The resultant CNV resembles aspects of 
exudative AMD and can easily be performed in rodents, producing robust subretinal 
vascular lesions within 14 days. L-CNV has become the “gold standard” in preclinical 
studies,6 despite limitations of using rodents.5 This model has been invaluable for the 
evaluation of the effects of drug therapies on CNV lesion progression7, 8  
Vascular endothelial growth factor (VEGF) has been recognized as a key proangiogenic 
factor in CNV. Targeting the VEGF pathway, using specific antibodies, antibody 
fragments, or aptamers, is a standard pharmacotherapeutic approach for wet AMD9 and 
has been previously tested in L-CNV experimental models.10, 11 Several methods for 2-
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dimensional (2D) evaluation of L-CNV lesions have been used including histological 
analysis and fluorescein angiography.12 Measuring L-CNV lesion volume using stained 
choroidal flatmounts ex vivo allows 3-dimensional (3D) measurement of lesion size, 
which is more informative than measuring lesion area alone and has become widely 
accepted as a quantitative method to indicate drug efficacy in ameliorating CNV 
lesions.5, 13, 14
Although ex vivo lesion measurements of L-CNV are robust and powerful, in vivo 
imaging analysis of lesions would allow longitudinal studies. Optical coherence 
tomography (OCT) is a non-invasive, in vivo imaging technique that generates high 
resolution, cross sectional images of biological systems.15 The technique has found 
extensive use in ophthalmology15, 16 providing detailed images for both the anterior and 
posterior segments of the eye17 and has become an essential tool for the clinical 
evaluation of ocular pathologies such as wet AMD,18 retinal tumors,19-21 and retinal 
detachment.22 
Paralleling its rise to clinical prominence, OCT has been used preclinically to monitor 
disease progression, and OCT images have been shown to be comparable to 
histological characteristics in disease models,23-26 including L-CNV.12, 27 However, to our 
knowledge, 3D quantification of lesions in OCT images has previously used specialized 
software that is not readily available or compatible with different systems. Moreover, the 
correlation between calculated lesion volume from OCT images and ex vivo choroidal 
flatmount 3D quantification has not been shown previously. In this study, we show that 
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simple quantification of lesion volumes from OCT images provides reproducible and 




All animal experiments followed the guidelines of the Association for Research in Vision 
and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision 
Research and were approved by the Indiana University School of Medicine Institutional 
Animal Care and Use Committee. Wild-type female C57BL/6J mice, 6–8 weeks of age, 
were purchased from Jackson Laboratory (Bar Harbor, ME). These mice were 
anesthetized by intraperitoneal injections of 17.5 mg/kg ketamine hydrochloride and 2.5 
mg/kg xylazine. 
Laser-Induced model of Choroidal Neovascularization 
Laser photocoagulation was performed as previously described.28, 29 Briefly, eyes were 
dilated using 1% tropicamide, then underwent laser treatment using 50 µm spot size, 50 
ms duration, and 250 mV pulses of an ophthalmic argon green laser, wavelength 532 
nm, coupled to a slit lamp. A coverslip was used to allow viewing of the posterior pole of 
the eye. Each eye received 3 laser burns centered around the optic nerve at 12, 3, and 
9 o’clock positions. The laser-induced damage to Bruch’s membrane was identified by 
the appearance of a bubble at the site of laser application. Lesions in which bubbles 
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were not observed were excluded from the study. Where indicated, intravitreal injections 
of anti-mouse VEGF164 neutralizing antibody (R&D Systems, Minneapolis, MN) (5 
ng/eye) or vehicle (phosphate buffered saline) were given immediately after laser in a 
0.5 µL volume using a 33-gauge needle. The needle was kept in place for 1 minute to 
prevent the reflux of solution when the needle was removed. Eyes were numbed with 
tetracaine solution before the injection, and triple antibiotic ointment was used 
immediately after the injection to prevent infection. A masked researcher undertook 
imaging and analysis to avoid bias. 
Optical Coherence Tomography 
OCT was performed at the indicated times using the Micron III intraocular imaging 
system (Phoenix Research Labs, Pleasanton, CA) or the InVivoVue OCT system 
(Bioptigen Inc., Research Triangle Park, Durham, NC). These are the two most 
commonly used rodent OCT systems. For the Micron system, imaging was done by a 
single experimenter (RSS). Before the procedure, eyes were dilated with 1% 
tropicamide solution and lubricated with hypromellose ophthalmic demulcent solution 
(Gonak) (Akorn, Lake Forest, IL). Mice were then placed on a custom heated stage that 
moves freely to position the mouse eye for imaging. Several horizontal and vertical 
images were taken per lesion to allow calculation of CNV lesion volume. 
For the InVivoVue system, experiments were done separately by a second laboratory, 
with imaging conducted by JQ. Pupils of mouse eyes were dilated with 1% atropine and 
2.5% phenylephrine hydrochloride. Mice were then anesthetized. One drop of 2.5% 
hydroxypropyl methylcellulose was administrated to eyes before examination. Three 
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lateral images (nasal to temporal) were collected, starting at the meridian crossing 
through the center of the optic nerve head (ONH), and the corresponding L-CNV injury 
spots were identified by contrasts. Composite fundus images (1.4x1.4 mm, 
400x100x1x1) were taken centered on the ONH. Corresponding high resolution B-scan 
(1.4x1.4 mm, 400x400x1x1) images were then obtained from swept L-CNV spots. 
Quantification of Lesions as Ellipsoids 
Quantification was performed as in Fig. 1, for images obtained from the Micron system. 
The widest section of the lesions from perpendicular planes were used to calculate 
ellipsoid volume using the formula  =


 where a, b, and c are the radii of the three 
axes of the ellipsoid. The radii were manually drawn and measured using ImageJ 
software. The CNV lesion borders were defined from the onset of thickening of the 
choroidal layer horizontally to the borders of the hyperreflective lesion vertically. The 
lesion borders were defined similarly for images obtained using the InVivoVue system. 
In this case, quantitative measures, width (a) and depth (b) of the lesion were 
measured from the exported central image in B-scanned compositions. The length (c) of 
the lesions was calculated from en face images as the difference in distance between 
the beginning and the end of the lesion. Images from both the Micron III and InVivoVue 
systems were analyzed by two independent graders (RSS and MNO) for interobserver 
comparison. The volumes of the three lesions in each eye were averaged and 
considered as an n=1 for statistical analysis. 
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Choroidal flatmount preparation and ex vivo CNV lesion volume quantification 
Fourteen days post-laser, L-CNV mice were euthanized by carbon dioxide asphyxiation 
followed by cervical dislocation. Eyes were enucleated and fixed in 4% 
paraformaldehyde (PFA) overnight. The anterior segment and the retina were removed, 
and the remaining RPE/choroid/sclera was permeabilized by incubation with 0.3% 
Triton X-100 followed by incubation with rhodamine labeled Ricinus communis 
agglutinin I (Vector Labs, Burlingame, CA), in the dark for 45 minutes, to stain blood 
vessels. The staining step was followed by two washes with Tris buffered saline with 
0.1% Tween-20 (TBST). Flatmounts of the choroid were prepared and mounted with 
Vectashield mounting medium (Vector Labs, Burlingame, CA) and Z-stack images were 
taken on an LSM700 confocal microscope (Zeiss, Thornwood, NY, USA). ImageJ 
software was used to analyze Z-stack images; the summation of the whole stained area 
in each section, multiplied by the distance between sections (3 µm) was used as an 
index for the CNV lesion volume.28 The volumes of the three lesions in each eye were 
averaged and considered as an n=1 for statistical analysis. 
Statistical analysis 
Statistical analysis was performed with GraphPad Prism 6 software. CNV volume was 
compared between treatments using the Mann-Whitney test. The Spearman correlation 
coefficient was used to assess the correlation between lesion volumes measured by 
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OCT and choroidal flatmounts. P-values ≤ 0.05 were considered statistically significant. 
Results 
Ellipsoid quantification in vivo is comparable to ex vivo analysis in L-CNV 
Although Z-stack analysis of wholemounts gives robust and reproducible data, we 
sought a simple means of evaluating L-CNV lesion volume in vivo. Mice underwent 
OCT 14 days post-laser. Comparing volumetric measurements of OCT and agglutinin-
stained wholemount Z-stacks, significant correlation was observed by two independent 
graders; grader 1 with ρ = 0.79, P<0.01 and grader 2 ρ = 0.78, P<0.05 (Fig. 2). The 
intraobserver correlation (based on repeated analysis of the same dataset) was ρ = 0.9, 
P<0.001, while the interobserver correlation was ρ = 0.73, P<0.05. 
Ellipsoid quantification is sensitive to different treatment conditions 
In the L-CNV model, anti-VEGF antibodies have previously been shown to reduce CNV 
lesion volume, based on Z-stack image quantification, compared to vehicle treated 
controls.30 We first sought to reproduce this amelioration in the CNV lesion size using 
the L-CNV mouse model and to compare the difference between treatment groups 
using both confocal microscopy and OCT. Quantification of CNV lesion volume using 
the standard Z-stack image method showed the expected significant reduction, about 
35%,31 in lesion volume after anti-VEGF treatment compared to vehicle controls (Fig. 3). 
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Interestingly, CNV lesion volume calculated using this method from OCT images 
obtained 7 days after laser and injection also demonstrated a significant reduction, 
likewise about 35%, after anti-VEGF treatment (Fig. 4). Similar results were obtained 
from images after 14 days (Fig. 4). Importantly, OCT volume measurements 
significantly correlated with those measured by Z-stack quantification, after 7 days (ρ = 
0.82, P<0.01) (Fig. 5A), and after 14 days (ρ = 0.82, P<0.01) (Fig. 5B). 
Ellipsoid quantification is OCT platform-independent 
To validate that our ellipsoidal volume measurement technique could be applied to 
images from another automated OCT system, we evaluated L-CNV lesions using OCT 
images obtained with the InVivoVue system. Laser burns were applied to mouse eyes 
and after 10 days, lesions were evaluated by OCT in vivo. Lesion volumes were 
calculated by ellipsoid volume equation, and again compared to volumetric 
measurements of CNV lesion volumes from agglutinin stained choroidal flatmounts ex 
vivo after 14 days. Interestingly, a significant correlation was again observed between 
ellipsoid volume calculation and confocal Z-stack images (Fig. 6) (ρ = 0.75, P<0.05). 
Similar correlation values were obtained by a second grader to account for 
interobserver variability (data not shown). Moreover, removing the peak point, which 
might be an outlier, did not change the correlation (ρ = 0.75, P<0.05). 
Discussion 
OCT imaging represents an essential adjunct in clinical diagnosis and monitoring of 
numerous ocular diseases, such as AMD.20, 32 Evaluation of L-CNV in vivo using OCT 
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imaging has been previously studied in different species such as monkeys,33, 34 
rabbits,35 and rats.27, 36, 37 Others have evaluated OCT in the mouse model of L-CNV 
used here by comparing OCT imaging to immunostaining and histological analyses.12,
38, 39 However, in this study, we compared for the first time OCT quantification of L-CNV 
lesions to the robust and commonly used ex vivo agglutinin stained choroidal 
wholemount quantification method, which allows volumetric measurements of L-CNV 
lesions through Z-stack sections.5, 13 We saw excellent correlation between the two 
methods using different OCT imaging systems. 
Quantification of OCT images usually requires specialized, proprietary software that is 
not necessarily compatible with multiple imaging systems. In this study, we showed that 
quantitative OCT analysis by a simple method allowed in vivo evaluation and monitoring 
of choroidal lesions in the L-CNV model using two of the most commonly used OCT 
imaging systems. Although we used ImageJ for analysis, the radii measurements 
needed for ellipsoid volume could be done using any image-editing program. 
Quantification of L-CNV lesions, obtained from either Micron or InVivoVue OCT images, 
using an ellipsoid volume calculation, provides reproducible and comparable results to 
the standard ex vivo quantification method. Consistently, we observed a significant 
correlation, by two independent graders, between OCT images obtained at day 7, 10, or 
14 post-laser, and Z-stack confocal measurements at day 14. However, due to the 
difference in scaling of the Micron III and InVivoVue imaging systems; calculated lesion 
volumes by Micron OCT were uniformly larger than those calculated by confocal 
microscopy. Tissue shrinkage during fixation may also contribute to this finding. 
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Alternatively, since the length of the lesion (dimension c) on the InVivoVue was 
obtained from en face images directly, not from vertical scans as was done with the 
Micron III system, this might induce some differences in the final calculation. Thus, 
using the same volumetric measurement system throughout the analysis of an 
experiment is important. 
Our method also applies to OCT imaging to assess pharmacotherapeutic efficacy. Here, 
as proof of concept, we used the standard anti-VEGF antibody treatment, versus 
vehicle treatment, to ameliorate CNV lesion volume. To our knowledge, this is the first 
use of OCT to show therapeutic effect in the murine L-CNV model, although OCT has 
been used similarly in macaques.34 As we show, OCT can be used to monitor drug 
response longitudinally in the same animal, reducing animal usage and enabling time-
course comparisons. For instance, we noted that mean L-CNV lesion volumes 
decreased from Day 7 to Day 14 (Fig. 4, 5), but the distinction between anti-VEGF and 
vehicle treatments remained about 35% as previously shown.31  
OCT analysis is also rapid. Preparation of choroidal flatmounts for the quantification of 
L-CNV lesion volume is a technically involved and time-consuming technique, requiring 
at least one overnight step and considerable confocal imaging time, as well as 
expensive reagents (fluorescent agglutinin in particular).5 Conversely, acquiring multiple 
images on an OCT system takes about 5 –10 minutes per eye followed by 5 minutes for 
calculation of the lesion volume. Therefore, our ellipsoid volume quantification method 
represents an inexpensive, rapid, yet reliable quantification method for lesions from 
Page 13 of 45
Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801































































OCT images. Despite that, it is important to mention that OCT quantification is not a 
replacement for the Z-stack confocal measurement. However, it might provide an early 
prediction of therapeutic effects as well as a second evaluation method for CNV lesion 
volume. 
One limitation of this method is the manual detection of CNV lesion dimensions, which 
might introduce bias to treatment conditions. However, this can be avoided when the 
experimenter is masked to treatments throughout imaging and analysis, as well as 
using at least two independent graders for volumetric analysis. True CNV lesion shape 
is likely not a simple ellipsoid; therefore, using a simple ellipsoid volume measurement 
may overestimate irregularly shaped lesions.39 However, following from this, in 
experiments comparing CNV-lesion reducing therapies to control conditions it is likely 
that our method would be quite conservative (by potentially overestimating lesion 
volume and thus underestimating treatment effects), which might be considered as a 
strength.  Like any OCT analysis, our method also requires a clear cornea and lens, and 
lesions in or near the central retina. This method is also limited to disease models that 
involve localized lesions that can be demarcated by OCT, such as L-CNV. However, a 
strength of our method is that it can be used to calculate volumes from the L-CNV 
murine model using different automated imaging systems, specifically the Micron and 
InVivoVue products. 
This study provides evidence that OCT is a valuable tool to rapidly and quantitatively 
evaluate response to drug therapies for choroidal neovascularization using the L-CNV 
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mouse model. Our simple ellipsoidal quantification method may also be applied to the 
analysis of other focal intraocular lesions and provides rapid analysis for preclinical 
testing of possible therapeutic agents. 
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Figure 1. Determination of ellipsoid axes in Micron OCT images. A) Representative 
images showing the horizontal plane of OCT imaging (red line) in the bright field fundus 
photographs and the radii a (width) & b (depth relative to the retina) on the 
corresponding zoomed in OCT scan. B) Representative images showing the vertical 
plane in the bright field image and radius c (length) on the corresponding orthogonal 
zoomed in OCT scan. C) A schematic diagram showing an ellipsoid with labeled axes 
corresponding to the OCT images, and the equation used in calculating ellipsoid 
volume. Scale bars = 100 µm. Abbreviations; ganglion cell layer (GCL), outer nuclear 
layer (ONL), retinal pigment epithelium (RPE). 
Figure 2. L-CNV lesion volumes calculated from Micron OCT images obtained 14 days 
post-laser, analyzed by two independent graders, correlate with those calculated based 
on choroidal flatmount Z-stacks. Grader 1 (left) Spearman’s ρ = 0.79, P<0.01. Grader 2 
(right) ρ = 0.78, P<0.05. n = 10. 
Figure 3. Choroidal flatmounts stained with agglutinin show a significant reduction in 
CNV lesion volume after anti-VEGF treatment. A) Representative images from confocal 
microscopy for CNV lesions from vehicle-treated (left) and anti-VEGF-treated eyes 
(right). Scale bars = 50 µm. B) Quantification of the CNV lesion volume from Z-stack 
images using ImageJ software demonstrated a significant reduction in CNV lesion 
volume after anti-VEGF intravitreal injection compared to vehicle treated controls, 
**P<0.01, Mann-Whitney test. Mean ± SEM, n = 6. 
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Figure 4. Quantification of L-CNV lesions by OCT shows a significant reduction in lesion 
volume after anti-VEGF treatment. A) Representative images of L-CNV lesions, shown 
between red brackets, from vehicle-treated (left) and anti-VEGF-treated eyes (right) 
obtained after 7 days (top) and 14 days (bottom). B) Quantification of the CNV lesion 
volume calculated as an ellipsoid, showing a significant reduction in CNV lesion volume 
after anti-VEGF intravitreal injection compared to vehicle treated controls, after both 7 
and 14 days, with **P<0.01, Mann-Whitney test. Note different y-axis scales. Mean ± 
SEM, n = 6. 
Figure 5. L-CNV lesion volumes following treatments calculated from Micron OCT 
images correlate with those calculated based on choroidal flatmount Z-stacks. (A) OCT 
calculations at 7 days, Spearman’s ρ = 0.82. (B) OCT calculations at 14 days, ρ = 0.82. 
Vehicle-treated, blue, and anti-VEGF-treated eyes, red. P<0.01, n = 6 per treatment. 
Note different y-axis scales. 
Figure 6. L-CNV lesion volumes calculated from InVivoVue OCT images obtained 10 
days post-laser correlate with those calculated based on choroidal flatmount Z-stacks. 
A) Representative images showing the horizontal plane of OCT imaging (green line) in
the en face image and the corresponding B-scan focus on the optic nerve head (ONH). 
Scale bar = 34 µm. B) Representative images showing the en face image and the 
corresponding B-scan at an L-CNV lesion (arrow). C) A significant correlation is 
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observed between 3D measurements of OCT images and confocal Z-stack images, 
Spearman’s ρ = 0.75, P<0.05, n = 10. 
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Figure 1. Determination of ellipsoid axes in Micron OCT images. A) Representative images showing the 
horizontal plane of OCT imaging (red line) in the bright field fundus photographs and the radii a (width) & b 
(depth relative to the retina) on the corresponding zoomed in OCT scan. B) Representative images showing 
the vertical plane in the bright field image and radius c (length) on the corresponding orthogonal zoomed in 
OCT scan. C) A schematic diagram showing an ellipsoid with labeled axes corresponding to the OCT images, 
and the equation used in calculating ellipsoid volume. Scale bars = 100 µm. Abbreviations; ganglion cell 
layer (GCL), outer nuclear layer (ONL), retinal pigment epithelium (RPE).  
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Figure 2. L-CNV lesion volumes calculated from Micron OCT images obtained 14 days post-laser, analyzed by 
two independent graders, correlate with those calculated based on choroidal flatmount Z-stacks. Grader 1 
(left) Spearman’s ρ = 0.79, P<0.01. Grader 2 (right) ρ = 0.78, P<0.05. n = 10.  
82x35mm (600 x 600 DPI)  
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Figure 3. Choroidal flatmounts stained with agglutinin show a significant reduction in CNV lesion volume 
after anti-VEGF treatment. A) Representative images from confocal microscopy for CNV lesions from vehicle-
treated (left) and anti-VEGF-treated eyes (right). Scale bars = 50 µm. B) Quantification of the CNV lesion 
volume from Z-stack images using ImageJ software demonstrated a significant reduction in CNV lesion 
volume after anti-VEGF intravitreal injection compared to vehicle treated controls, **P<0.01, Mann-Whitney 
test. Mean ± SEM, n = 6.  
150x160mm (300 x 300 DPI)  
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Figure 4. Quantification of L-CNV lesions by OCT shows a significant reduction in lesion volume after anti-
VEGF treatment. A) Representative images of L-CNV lesions, shown between red brackets, from vehicle-
treated (left) and anti-VEGF-treated eyes (right) obtained after 7 days (top) and 14 days (bottom). B) 
Quantification of the CNV lesion volume calculated as an ellipsoid, showing a significant reduction in CNV 
lesion volume after anti-VEGF intravitreal injection compared to vehicle treated controls, after both 7 and 14 
days, with **P<0.01, Mann-Whitney test. Note different y-axis scales. Mean ± SEM, n = 6.  
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Figure 5. L-CNV lesion volumes following treatments calculated from Micron OCT images correlate with those 
calculated based on choroidal flatmount Z-stacks. (A) OCT calculations at 7 days, Spearman’s ρ = 0.82. (B) 
OCT calculations at 14 days, ρ = 0.82. Vehicle-treated, blue, and anti-VEGF-treated eyes, red. P<0.01, n = 
6 per treatment. Note different y-axis scales.  
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Figure 6. L-CNV lesion volumes calculated from InVivoVue OCT images obtained 10 days post-laser correlate 
with those calculated based on choroidal flatmount Z-stacks. A) Representative images showing the 
horizontal plane of OCT imaging (green line) in the en face image and the corresponding B-scan focus on the 
optic nerve head (ONH). Scale bar = 34 µm. B) Representative images showing the en face image and the 
corresponding B-scan at an L-CNV lesion (arrow). C) A significant correlation is observed between 3D 
measurements of OCT images and confocal Z-stack images, Spearman’s ρ = 0.75, P<0.05, n = 10.  
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